5248042026-01-012026-03-315248042026-03-315248042025-03-315248042025-04-012026-03-315248042026-01-012026-03-31in-capmkt:OtherExpenses1Member5248042026-01-012026-03-31in-capmkt:OtherExpenses2Member5248042025-04-012026-03-31in-capmkt:OtherExpenses1Member5248042025-04-012026-03-31in-capmkt:OtherExpenses2Member5248042026-03-31OtherNoncurrentFinancialAssetsDomain15248042026-03-31OtherNoncurrentAssetsDomain15248042026-03-31OtherNoncurrentAssetsDomain25248042026-03-31OtherCurrentFinancialAssetsDomain15248042026-03-31OtherCurrentAssetsDomain15248042026-03-31OtherNoncurrentFinancialLiabilitiesDomain15248042026-03-31OtherNoncurrentFinancialLiabilitiesDomain25248042026-03-31OtherNoncurrentLiabilitiesDomain15248042026-03-31OtherCurrentFinancialLiabilitiesDomain15248042026-03-31OtherCurrentFinancialLiabilitiesDomain25248042026-03-31OtherCurrentLiabilitiesDomain15248042026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15248042026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25248042025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15248042025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25248042026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15248042025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15248042026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524804AUROPHARMANOTLISTEDINE406A01037AUROBINDO PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-05-212026-05-12INRMillionsQuarterlyFourth quarterSingle segmentPharmaceutical products2026-05-2116:30:002026-05-2118:25:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31UnauditedConsolidated88533400000117040000089703800000250535000009314800000-776000001373980000098210000047857000002297510000076773400000129304000000129304000003990300000-292600000369770000009232700000000-2430000092084000007905600000171140000009212600000-420000017118200000-4200000580800000115.8615.860015.8615.861.The above consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <BR> 2.The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended. <BR> 3.The above consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 21, 2026. The results for the year ended March 31, 2026 has been audited and for the quarter ended March 31, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2026 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2026. <BR> 4.The Group operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment". <BR> 5.During the year ended March 31, 2026: <BR> (i) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics B.V., Netherlands through CuraTeQ Biologics Private Limited, India (wholly owned subsidiary) on May 28, 2025. <BR> (ii) The Company, incorporated a step-down subsidiary, Cresedemo Pharma LLC through Aurobindo Pharma USA Inc., (wholly owned subsidiary) on June 13, 2025. <BR> (iii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD. through Helix Healthcare B.V., The Netherlands, (wholly owned subsidiary) on September 17, 2025. <BR> (iv) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics (Malta) Limited through CuraTeQ Biologics B.V., The Netherlands, (wholly owned subsidiary) on September 26, 2025. <BR> (v) Pharmacin B.V (wholly owned subsidiary of Agile Pharma BV) merged with Agile Pharma BV (wholly owned subsidiary of Helix Healthcare B.V., The Netherlands) w.e.f. July 1, 2025. <BR> (vi) Helix Healthcare B.V, The Netherlands, (wholly owned subsidiary) has transferred its 100% stake in CuraTeQ Biologics s.r.o., Czech Republic (wholly owned subsidiary) to CuraTeQ Biologics B.V, The Netherlands (wholly owned subsidiary) w.e.f. July 29, 2025. <BR> (vii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma Chile SpA through Helix Healthcare B.V, (wholly owned subsidiary) on October 07, 2025. <BR> (viii) The Company, incorporated a step-down subsidiary, Eugia Pharma Chile SpA through Eugia Pharma B.V, (wholly owned subsidiary) on October 07, 2025. <BR> (ix) The Company, incorporated a step-down subsidiary, Aurobindo Pharma Philippines Inc. through Helix Healthcare B.V, (wholly owned subsidiary) on January 23, 2026. <BR> (x) The Company, incorporated a wholly owned subsidiary, Engenra Biologics Private Limited on February 24, 2026. <BR> (xi) The Company, acquired Diadame Pharma SARL, Senegal through its wholly owned step-down subsidiary Arrow Generiques SAS on January 01, 2026. <BR> <BR> 6.During the year, Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, has entered into a definitive agreement to acquire 100% of membership interest in Lannett Company LLC. The proposed transaction is subject to certain regulatory approvals. Accordingly, no financial impact has arisen in the quarter and year ended March 31, 2026. <BR> 7.On January 01, 2026, Auropharm Limited (a wholly owned subsidiary of the Company), signed a Business transfer agreement to purchase non-oncology prescription formulations business from M/s Khandelwal Laboratories Private Limited on a going concern basis. The acquisition includes transfer of Brands, workforce etc., for a total consideration of Rs. 3,250 million, consisting of an upfront cash payment of Rs. 3,000 million, and a deferred consideration upto Rs. 250 million which is payable subject to certain conditions precedence. <BR> 8.On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, (‘Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability (arising out of past service cost) and increase in leave liability aggregating Rs. 653.3 million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount under “Exceptional Items” in the Consolidated Statement of Profit and Loss for the quarter ended December 31, 2025 and year ended March 31, 2026. The Group continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits. <BR> <BR> 9.The Board of Directors at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of Rs. 1 each (representing 0.93% of the total number of equity shares of the Company) for an aggregate value not exceeding Rs. 8,000.0 million (Buyback Size) (excluding transaction cost) at a maximum buy back price of Rs. 1,475/- per equity share. <BR> <BR> The buyback offer is made to all of the equity shareholders of the Company, including the promoters and members of the promoter group of the Company (as defined under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011), who hold Equity Shares as of the record date (April 17, 2026), on proportionate basis through the tender offer route in accordance with the Companies Act, 2013, as amended, rules made thereunder, the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("Buyback Regulations") and other applicable laws. <BR> <BR> Pursuant to the buyback offer, 5,423,728 equity shares were accepted and consideration of Rs. 8,000.0 million was paid to eligible shareholders on May 07, 2026. <BR> <BR> 10.The figures for the current quarter and quarter ended March 31, 2025, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and March 31, 2025, respectively and published year to date figures up to third quarter ended December 31, 2025 and December 31, 2024, respectively, which were subject to limited review by the statutory auditors. <BR> 2025-04-012026-03-31AuditedConsolidated336530800000492090000034145170000010305190000034779800000-2948100000519017000003839700000177819000008128820000028969510000051756600000-6533000005110330000017361400000-1272600000160888000000350145000000001520000035029700000196520000005468170000035047500000-1780000054699400000-17700000580800000137832890000060.3460.340060.3460.34Foreign Exchange Loss (net)481600000Other Expenses22493500000Foreign Exchange Loss (net)100700000Other Expenses811875000001432993000003008830000008001500000227650000002204730000001088400000195040000007570000054990000007525100000148359000008283200000257934000000120529400000747240000070943700000719140000002678890000017870000010095000001783072000002168000002803410000032708750000000585021500000580800000378328900000378909700000-816000003788281000008027500000000534810000013375600000400410000030600000000536360000025803300000687345000001918800000537539000005567270000044083500000168490700000626300000035304000002106000000018039010000000206193400000585021500000Other Financial assets5499000000Other non-current assets3758900000Non - current tax assets4524300000Other Financial assets1009500000Other current assets28034100000lease liabilites2929400000Other financial liabilities2418700000Other non-current liabilities5363600000Lease liabilites1037000000Other financial liabilities43046500000Other current liabilities62630000003523100000-14997600000-117073000000-42028000000015560000000128157000000560740000001778190000001996400000010571500000022098000002270000032908000000005464000000937000000224807000007358400000000018320300000055263700000030317000005870000078776000000000462500000268577000000004189000000000000000000022700000328560000003542200000-345843000000000000071986000001303980000010854000002324000000344090000000-1269150000079879000008288200000162761000005563790000071914000000Remeasurement of defined employee benefit liability121600000Equity investments through other comprehensive income25300000146900000Remeasurement of defined employee benefit liability73700000Equity investments through other comprehensive income355000001092000003550000027000000Exchange differences on translating the financial statements of foreign operations.77942000007794200000Exchange differences on translating the financial statements of foreign operations.195698000001956980000000790560000019652000000AuditedtrueDeloitte Haskins & Sellstrue2028-04-30